Physician profile
William Shoemaker
NPI 1740642925
$5,687.22
in general payments reported to CMS, 2019-2025
20 companies · $1,577 in 2025
The $1,577 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $333 · 2023: $1,308 · 2024: $2,468 · 2025: $1,577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,354.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,558.93 | 2022-2025 | Enbrel, Otezla, Krystexxa |
| Abbvie INC. | $1,002.39 | 2022-2025 | Rinvoq, Humira, Skyrizi |
| Ucb, INC. | $751.72 | 2022-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $545.37 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $316.12 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $285.51 | 2023-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $263.36 | 2023-2025 | Benlysta |
| Lilly USA, LLC | $230.21 | 2022-2025 | Taltz, Zepbound |
| Radius Health, INC. | $145.52 | 2023-2025 | Tymlos |
| Fresenius Kabi USA, LLC | $109.46 | 2023-2025 | Tyenne, Idacio |
| Organon LLC | $98.91 | 2024-2025 | Hadlima, Nexplanon |
| Aurinia Pharma U.S., INC. | $98.34 | 2023-2025 | Lupkynis |
| Janssen Biotech, INC. | $62.81 | 2023-2025 | Tremfya |
| Sobi, INC | $56.77 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $51.59 | 2023-2025 | Orencia |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $24.25 | 2024 | Monoferric |
| Genzyme Corporation | $23.89 | 2024 | |
| Sandoz INC. | $23.69 | 2024 | Hyrimoz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.02 | 2024 | Cyltezo |
| Genentech USA, INC. | $16.36 | 2025 | Actemra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Shoemaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.